ACTIMMUNE ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 326 | Osteopetrosis | 3 |
326. Osteopetrosis
Clinical trials : 18 / Drugs : 43 - (DrugBank : 14) / Drug target genes : 17 - Drug target pathways : 82
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02666768 (ClinicalTrials.gov) | February 22, 2016 | 23/6/2015 | ACTIMMUNE in Intermediate Osteopetrosis | Open-label Early Phase 2 Study With a Single Arm of Interferon Gamma-1b Treatment of Osteopetrosis | Osteopetrosis | Drug: Interferon gamma-1b | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | University of Minnesota;Horizon Pharma Ireland, Ltd., Dublin Ireland | Completed | 1 Year | N/A | All | 5 | Phase 2 | United States |
| 2 | NCT02584608 (ClinicalTrials.gov) | January 1, 2016 | 20/10/2015 | Use of ACTIMMUNE in Patients With ADO2 | Phase 2a Study of Interferon Gamma-1b for the Treatment of Autosomal Dominant Type 2 Osteopetrosis | Autosomal Dominant Osteopetrosis Type 2 | Drug: ACTIMMUNE | Indiana University | Horizon Pharma Ireland, Ltd., Dublin Ireland | Completed | 3 Years | 65 Years | All | 12 | Phase 2 | United States |
| 3 | NCT00043329 (ClinicalTrials.gov) | January 2002 | 7/8/2002 | Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant Osteopetrosis | Post-Marketing Surveillance Study of Actimmune (Interferon Gamma-1b) in Patients With Severe Malignant Osteopetrosis | Osteopetrosis | Drug: Actimmune Registry | InterMune | NULL | Completed | N/A | N/A | Both | 6 | United States |